Managing breast cancers with low estrogen receptor and HER2 by drugging both.

Abstract

Low estrogen receptor (ER) levels in breast tumors are associated with poorer response to antiestrogen therapy. Finn and colleagues identify low ER levels as a biomarker predicting benefit from the addition of the EGFR/HER2 dual inhibitor lapatinib to an antiestrogen treatment regimen in patients with metastatic ER(+)/HER2(-) breast cancer.

• Authors: Todd W Miller
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 20 Issue 3 Pg. 528-30 (Feb 01 2014) ISSN: 1557-3265 [Electronic] United States
• PMID: 24352641 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Comment)
• Copyright: ©2013 AACR.

Chemical References

• Quinazolines
• Receptors, Estrogen
• Receptors, Progesterone
• Lapatinib

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (metabolism)
• Female
• Humans
• Lapatinib
• Quinazolines (administration & dosage)
• Receptors, Estrogen (biosynthesis)
• Receptors, Progesterone (biosynthesis)